Venn Life Sciences Holdings PLC Skin science patent grant

TIDMVENN

Venn Life Sciences Holdings PLC

19 June 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Venn's first skin science patent grant ignites Innovenn's commercialisation stage

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has secured its first skin science patent for its unique anti-acne complex from the European Patent Office. The Company has also commenced commercial discussions on Labskin, the breakthrough research grade human skin testing platform.

This clinically proven Blemish Control Technology, developed by dermatologists over five years of scientific research, clinical and home usage trials, uniquely delivers a natural blend of actives deeper and faster into the epidermal skin layer than other commercially available treatments. The active complex reduces bacteria, inflammation, excess oiliness and blocked pores, resulting in noticeably clearer skin in less than four hours.

This breakthrough enables a compelling scientific platform for the commercial development of a new blemish management technology brand, expected to launch later this year.

Meanwhile, commercial partnership discussions have commenced on Labskin following the establishment of new Innovenn laboratories and offices on the Innovation Campus at Sand Hutton, UK and the recruitment of a skin science management team. First revenue flows from Labskin are expected later this year.

Tony Richardson, CEO of Venn Life Sciences commented: "After five years of dermatological research, testing and consumer trials, this patent grant confirmation from the European Patent office is a substantial step forward in the commercialisation of this unique anti-acne complex. Since our acquisition of the assets of Evocutis Plc. in March of 2014, Innovenn have made tremendous progress in terms of bringing our anti-acne and living skin equivalent technology to the marketplace."

Enquiries:

 
 Venn Life Sciences Holdings Plc                         www.vennlifesciences.com 
 Tony Richardson, Chief Executive                            Tel: +353 154 99 341 
  Officer 
 Declan Service, Managing Director                            Tel: +353 877705506 
  Orla McGuinness, Marketing Manager 
 
 Zeus Capital (Nominated Adviser 
  and Broker) 
 Ross Andrews/Andrew Jones (Corporate                          Tel: 0161 831 1512 
  Finance) 
 Dominic Wilson (Institutional                                 Tel: 020 7533 7727 
  Sales) 
 
 Walbrook PR Ltd                        Tel: 020 7933 8787 or venn@walbrookpr.com 
 Paul McManus                                                  Mob: 07980 541 893 
 Lianne Cawthorne                                              Mob: 07584 391 303

About InnoVenn

InnoVenn is a market development accelerator dedicated to rapidly commercializing proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASFFESAFLSEIM

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024